menu
    • menu
    [{"orgOrder":0,"company":"Cytocom","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Merger","leadProduct":"CYTO-200","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytocom \/ Cleveland Clinic","highestDevelopmentStatusID":"9","companyTruncated":"Cytocom \/ Cleveland Clinic"},{"orgOrder":0,"company":"Cytocom","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"CYTO-201","moa":"Mu opioid receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytocom \/ Cleveland Clinic","highestDevelopmentStatusID":"9","companyTruncated":"Cytocom \/ Cleveland Clinic"},{"orgOrder":0,"company":"Cytocom","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CYTO-201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytocom \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytocom \/ Inapplicable"},{"orgOrder":0,"company":"Cytocom","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cytocom \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytocom \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Cytocom

    Menu

    Cytocom

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cytocom

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Cytocom

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYTO-200

                            Therapeutic Area : Immunology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Cleveland Clinic

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.

                            Details : Combined public entity to develop and commercialize next-generation immune therapies like CYTO-200, that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions.

                            Product Name : CYTO-200

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            February 17, 2021

                            Lead Product(s) : CYTO-200

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Cleveland Clinic

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cytocom

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Cytocom

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naltrexone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytocom Updates Investigational New Drug Application for Phase 2 Clinical Trial of CYTO-205 for the Treatment ...

                            Details : Cytocom has submitted an Investigational New Drug (IND) application with updated protocols to the FDA to begin a Phase 2 clinical trial, to evaluate the safety and efficacy of CYTO-205 to slow or halt the progression of the SARS-CoV-2, the virus that cau...

                            Product Name : CYTO-205

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 16, 2021

                            Lead Product(s) : Naltrexone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cytocom

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Cytocom

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYTO-201

                            Therapeutic Area : Immunology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Cleveland Clinic

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Cytocom and Cleveland BioLabs Announce Definitive Merger Agreement

                            Details : Merger to create a single public company focused on the development and commercialization of immunotherapies for oncology, infectious disease, inflammation and auto-immune mediated conditions. Portfolio includes investigational drug, CYTO-201, for COVID-...

                            Product Name : CYTO-201

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 20, 2020

                            Lead Product(s) : CYTO-201

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Cleveland Clinic

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cytocom

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Cytocom

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYTO-201

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytocom, Inc. Announces Successful Completion of Type-B Pre-IND Meeting with FDA Regarding Phase 2 Trial of CY...

                            Details : Based on the FDA's feedback, Cytocom plans to revise the protocol of Company's planned Phase 2 clinical trial of CYTO-201 for the treatment of SARS-CoV-2 and quickly initiate enrollment.

                            Product Name : CYTO-201

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 29, 2020

                            Lead Product(s) : CYTO-201

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth